Chordoma: The Nonsarcoma Primary Bone Tumor by Chugh, Rashmi et al.
Chordoma: The Nonsarcoma Primary Bone Tumor
RASHMI CHUGH,a HUSSEIN TAWBI,d DAVID R. LUCAS,b J. SYBIL BIERMANN,c
SCOTT M. SCHUETZE,a LAURENCE H. BAKERa
aDepartment of Internal Medicine, Division of Hematology/Oncology, bDepartment of Pathology, and
cDepartment of Orthopedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; dDepartment of
Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh,
Pennsylvania, USA
Key Words. Chordoma • Bone tumors • Proton radiation
Disclosure: L.H.B. is an advisory board member of Ascenta Therapeutics, Inc., The Hope Foundation, NCCN Guidelines
Committee, and SARC (Sarcoma Alliance for Research through Collaboration) for which he receives no compensation. No other
potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.
ABSTRACT
Chordomas are rare, slowly growing, locally aggres-
sive neoplasms of bone that arise from embryonic
remnants of the notochord. These tumors typically
occur in the axial skeleton and have a proclivity for
the spheno-occipital region of the skull base and sa-
cral regions. In adults, 50% of chordomas involve the
sacrococcygeal region, 35% occur at the base of the
skull near the spheno-occipital area, and 15% are
found in the vertebral column. Craniocervical chor-
domas most often involve the dorsum sella, clivus,
and nasopharynx. Chordomas are divided into con-
ventional, chondroid, and dedifferentiated types.
Conventional chordomas are the most common. They
are characterized by the absence of cartilaginous or
additional mesenchymal components. Chondroid
chordomas contain both chordomatous and chon-
dromatous features, and have a predilection for the
spheno-occipital region of the skull base. This variant
accounts for 5%–15% of all chordomas and up to
33% of cranial chordomas. Dedifferentiation or sar-
comatous transformation occurs in 2%– 8% of chor-
domas. This can develop at the onset of the disease or
later. Aggressive initial therapy improves overall out-
come. Patients who relapse locally have a poor prog-
nosis but both radiation and surgery can be used as
salvage therapy. Subtotal resection can result in a sta-
ble or improved status in as many as 50% of patients
who relapse after primary therapy. Radiation ther-
apy may also salvage some patients with local recur-
rence. One series reported a 2-year actuarial local
control rate of 33% for patients treated with proton
beam irradiation. The Oncologist 2007;12:1344–1350
INTRODUCTION
Chordoma is a rare primary bone tumor (Table 1) with an
incidence rate of0.1 per 100,000 per year, with around
25 afflicted persons diagnosed in the U.S. annually [1]. It
accounts for 1%– 4% of all primary malignant bone tu-
mors [2, 3]. Chordomas arise from embryonic remnants
of notochord and show a dual epithelial-mesenchymal
differentiation. Reaching maturity in the embryo at 11
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mm, the notochord obliterates and is displaced from the
central to the cranial and caudal positions. Microscopic
foci remain in the vertebral bodies at the cranial and cau-
dal ends of the embryo. Malignant transformation typi-
cally occurs in the third to fourth decades of life for
spheno-occipital lesions and in the fifth to sixth decades
for the sacrococcygeal type [4]. Histologically, they dis-
play lobules and vacuolated (physaliphorous), moder-
ately atypical, neoplastic cells across a myxoid stroma
separated by fibrous bands [5]. Given that they have an
ectodermal origin, chordomas are technically not sarco-
mas; however, they are traditionally classified and ap-
proached as sarcomas on the basis of being a primary
bone tumor [6].
Chordomas are usually relatively slow-growing, low-
grade malignancies. They arise from the sacrum in ap-
proximately 50%– 60% of cases, from the skull base
region (spheno-occipital/nasal) in approximately 25%–
35% of cases, from the cervical vertebrae in approxi-
mately 10% of cases, and from the thoracolumbar
vertebrae in approximately 5% of cases [3]. The median
age at presentation is around 60 years; however, presen-
tation with skull base tumors may occur at a younger age
and has been reported in children and adolescents [3].
Clinical presentation is usually with pain as the cardinal
symptom, whereas neurologic deficits tend to vary based
on the location of the lesion. Chordoma has been consid-
ered of low metastatic potential; however, distant metas-
tasis to lung, bone, soft tissue, lymph node, liver, and
skin has been reported in up to 43% of patients [7–9].
Metastatic sites, however, usually occur late in the
course of the disease. In most instances, control of pri-
mary disease remains the major therapeutic challenge.
Nonetheless, metastatic disease may be considered of ad-
verse prognostic significance because the median sur-
vival time was reported to be 12 months in a series of
28 chordoma patients after the development of distant
metastasis [6]. The overall median survival time with
chordoma has been estimated to be approximately 6
years, with a survival rate of 70% at 5 years, falling to
40% at 10 years. Of prognostic value is a chondroid his-
tology, which exhibits low-grade behavior and a favor-
able long-term outcome. Conversely, dedifferentiated
chordoma is observed in 5% of cases, has features of
high-grade spindle cell sarcoma, and demonstrates an ag-
gressive clinical course [10] (Figs. 1 and 2).
The therapeutic approach to chordoma has tradition-
ally relied heavily on surgical control. More recently, ra-
diation therapy has been demonstrated to be a valuable
modality for local control, particularly with the advent of
charged particle radiotherapy. Medical therapy contin-
ues to be suboptimal in this tumor, which is relatively re-
fractory to cytotoxic chemotherapy; however, newer
targeted agents may offer therapeutic alternatives.
Table 1. Classification of primary malignant bone tumors
I. Osteosarcoma






6. Other (telangiectatic, epithelioid, chondromyxoid
fibroma–like, chondroblastoma-like,
osteoblastoma-like, giant cell rich)
B. Intramedullary low grade
C. Juxtacortical high grade (high-grade surface
osteosarcoma)
D. Juxtacortical intermediate-grade chondroblastic
(periosteal osteosarcoma)


























G. Sarcoma, NOS; primary malignant lymphoma;
multiple myelomas are not included
Abbreviation: NOS, not otherwise specified.
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GENETICS
Genetic studies performed on chordomas include chromo-
some analysis, telomere reduction and telomere activity,
DNA microsatellite, loss of heterozygosity (LOH), and
clonality studies. Unfortunately, given the rarity of the tu-
mor, studies of molecular abnormalities are generally small
and often unvalidated. Various cytogenetic and molecular
findings indicate 1p36 loss as a consistent change in spo-
radic and inherited chordomas [11]. In addition, microsat-
ellite instability (MSI) and LOH studies performed on 12
chordomas detected MSI in 50% of patients at one or more
loci, and LOH was identified in two chordomas, one of
which had corresponding MSI [12].
Numerical and structural alterations in chromosomes 3
and 21 have also been observed. Many cases showed a hy-
podiploid or near diploid chromosome number [13]. Sand-
berg and Bridge [14] noted that about half of all chordomas
show chromosome aberrations of diverse nature, suggest-
ing that these alterations occur as late events in tumor pro-
gression. The retinoblastoma (RB) gene is a well-
characterized tumor-suppressor gene whose protein binds
nuclear DNA and plays a key role in cell-cycle regulation.
Inactivation of the RB gene has been associated with a num-
ber of malignant neoplasms. Chordomas have demon-
strated LOH at intron 17 of the RB gene in two of seven
samples studied [15].
A limited analysis of chromosome telomeres from chor-
domas has revealed lengthening in all four of four samples.
In marked contrast, telomere length reduction has been ob-
served during in vitro senescence of human fibroblasts and
most cancers [16]. Telomerase, the enzyme responsible for
maintenance of telomere length, has been identified in
about one half of the chordomas studied to date [17].
Clonality studies on eight cases of sacral chordomas indi-
cated a polyclonal origin of the tumor [4].
SURGERY
Surgery continues to be the primary modality in the man-
agement of chordomas. Rates of local recurrence, as well as
survival, appear to be dependent on the achievement of neg-
ative surgical margins, with recurrence rates on the order of
70% in cases where negative margins are not achieved. In a
series of 52 patients, Boriani et al. [18] reported that 100%
of patients treated with radiation alone, palliative therapy,
or intralesional intracapsular excision had local recurrence
within 17–20 months. In contrast, only 20% of patients had
local recurrence at 56–94 months after en bloc resection
with appropriate margins [18]. Similarly, Tzortzidis et al.
[19] used aggressive surgical approaches to achieve total
resection in up to 70% of patients, resulting in long-term
control in50% of cases.
The surgical techniques for margin-free, en bloc tumor
resection have been proven to be effective in terms of local
control and long-term prognosis for chordomas occurring
in the thoracic and lumbar spine [20–25]. Thus, efforts to
perform en bloc resections are warranted, even in the cer-
vical spine [26]. Surgical outcomes are dependent on loca-
tion and tumor size at diagnosis. Bulky tumors adjacent to
critical structures frequently preclude margin-negative re-
sections [27]. In the past, often the only surgery possible
was decompression or debulking of the tumor [28, 29]. Re-
cent advances in imaging techniques play an important role
in improving the prognosis of chordoma by discovering
small intraosseous tumors, which can be submitted more
easily to en bloc resection [30–33].
Recurrent tumors are generally more challenging for
Figure 1. Classic lobular architecture of chordoma. Fibrous
bands divide it into lobules containing cords of cohesive epi-
thelioid cells with abundant eosinophilic cytoplasm and round
nuclei within a myxoid matrix.
Figure 2. Physiliforous cells are characteristic of chordoma.
These cells have large, sharply delimited, clear vacuoles im-
parting a bubbly appearance.
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surgical interventions and clearly have worse overall out-
comes. This could be related, in part, to the more aggressive
biological behavior of a recurrent tumor [19]. The combi-
nation of palliative and/or debulking surgery with high-
energy radiation seems promising in recurrent tumors or in
tumors not suitable for en bloc surgery [34–37]. It is note-
worthy that outcome results show a large difference in the
local failure rate between patients treated for primary and
those treated for recurrent chordomas. In a series of 21 pa-
tients, local control of sacral chordomas treated with sur-
gery and radiation was achieved in 86% for primary lesions,
as opposed to 14% for recurrent lesions [38].
In addition to the technical difficulties obtaining nega-
tive margins, the surgical management of chordomas may
result in poor functional outcomes. For instance, resections
of sacral chordomas above the level of S2 are marked by
significant perioperative morbidity and long-term sequelae
[39, 40]. In fact, resections of both S2 roots result in urinary
and bowel incontinence, while the loss of both S3 roots may
result in substantial problems in a significant proportion of
patients.
RADIATION THERAPY
Chordomas are considered radioresistant tumors and re-
quire doses in excess of 60 Gy. However, these dose levels
cannot be safely delivered because they exceed the toler-
ance of most neurologic structures, especially the brain
stem and optic pathway [41–44]. Conventional radiother-
apy (RT) with high-energy photons up to a dose of 50–55
Gy does not provide a high local control rate [8, 45, 46].
Between 60 and 65 Gy is considered a minimum useful
dose, but higher doses have been favored in some series,
particularly when using particle radiation [47–51], al-
though a dose–response relationship has not been consis-
tently reported across all series [45, 52].
Surgery for skull base and upper cervical spine tumors
poses a risk of damage to normal structures, including the
spinal cord and cranial nerves. These same normal tissue
structures also impose a limitation on the external-beam RT
dose, which adds additional difficulty. The combination of
surgery and RT appears to be the best treatment for these
tumors [53–55]. The use of razoxane as a radiosensitizing
agent along with conventional RT was explored in a small
series and showed a trend for superior local control [56].
The advent of advanced imaging, planning, and delivery
of photon RT over the past one to two decades has provided
opportunities for delivering high doses of radiation safely to
patients with skull base and cervical spine tumors [57, 58].
However, an additional method for improving the physical
dose distribution of radiation treatment for chordomas is the
use of charged particles, especially protons. These ap-
proaches offer better tumor control and/or fewer side ef-
fects, such as contralateral hearing loss/brain atrophy and
radiation-induced second malignancies.
The best results in the treatment of chordomas of the
skull base are reported when using surgery and adjuvant
high-dose proton RT. The actuarial 5-year local control rate
was 73% using tumor doses of 66–83 cobalt Gray equiva-
lents (CGE) for 519 patients with skull base chordomas
treated with protons at the Massachusetts General Hospital
[53]. Hug et al. [59] reported an actuarial 3-year local con-
trol rate of 67% for 58 chordoma patients treated at the
Loma Linda University Medical Center with proton RT.
Tumor doses were in the range of 64.8–79.2 CGE. Noel et
al. [60] reported the results of combined photon and proton
RT in 45 patients with chordomas and chondrosarcomas of
the skull base treated with a median total tumor dose of 67
CGE (range, 60–70 CGE). Photons represented two thirds
of the total dose and protons represented one third. At 3
years, the local control rates for chordomas and chondro-
sarcomas were 83.1% and 90% [60].
Experience using particle therapy with particles heavier
than protons, such as helium and carbon ions, is limited. Be-
tween 1977 and 1992, Castro et al. [61] treated 223 patients
with helium ions (target dose, 65 CGE) at the Lawrence
Berkeley Laboratory; the actuarial 5-year local control rates
were 63% for chordomas and 78% for chondrosarcomas.
Compared with helium ions, carbon ions offer potential
biologic advantages and appear to be highly effective in the
treatment of chordomas. Schulz-Ertner et al. [49] reported
on a series of 54 chordoma patients treated with carbon ion
therapy, achieving a 3-year local control rate of 81%. Local
control rates at 3 years were at least comparable to those of
proton RT, while severe radiation-induced side effects were
minimized, allowing a target dose of 60 CGE to be deliv-
ered with a low risk for severe sequelae.
Extracranial chordomas are more difficult to treat than
tumors of the skull base. Radiosensitive structures as well
as larger setup errors limit the prescription dose. As a con-
sequence of suboptimal RT doses, local control rates have
been poor. The best results were obtained with heavy
charged particles. Schoenthaler et al. [62] treated 14 pa-
tients with helium or neon ions at the Lawrence Berkeley
Laboratory. Four of 14 patients were treated after gross tu-
mor resection. They reported a 5-year local control rate of
55%, with a trend for better local control in patients treated
with neon ions, compared with helium ions, and for four pa-
tients who received RT after gross tumor resection [62].
Berson et al. [63] reported a 5-year local control rate of
54% for 10 patients with chordomas and chondrosarcomas
of the cervical spine treated with charged particles at the
Lawrence Berkeley Laboratory. Similar results were ob-
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tained with protons in 14 patients with spinal and sacral
chordomas at the Massachusetts General Hospital, with a
5-year local control rate of 53% [59].
MEDICAL THERAPY
Chordomas are not reported to be sensitive to chemother-
apy, similar to many other low-grade malignancies. Ac-
cordingly, chemotherapy response has been reported in
patients with high-grade dedifferentiated chordomas,
which represent5% of all chordomas [64].
Anecdotal reports of responses to chemotherapy such as
vinca alkaloids and alkylating agents have been limited to
case reports [65–68]. The only prospective phase II clinical
trial using conventional chemotherapy in the treatment of
chordomas was conducted at the University of Michigan. A
topoisomerase I inhibitor, 9-nitro-camptothecin (9-NC),
was used to treat 15 patients with chordomas. Although
only one (7%) objective response rate was observed, 9-NC
appeared to delay progression of disease, with a median
3-month progression-free survival rate of 47%, and a
6-month progression-free survival rate of 33% [69].
The advent of molecularly targeted therapies has raised
interest for their use, particularly in low-grade malignan-
cies with poor response to chemotherapy. Casali et al. [70]
treated six chordoma patients with imatinib mesylate at 800
mg daily and observed nondimensional tissue responses,
marked by hypodensity and decreased contrast uptake on
computed tomography scan (and concordant changes on
magnetic resonance imaging). It was subsequently shown
that chordomas express platelet-derived growth factor re-
ceptor (PDGFR)- and its phosphorylated form, denoting
constitutive activation. That series was expanded to a mul-
ticenter phase II trial in Italy and Switzerland that enrolled
55 patients. In 44 patients evaluable for antitumor response,
37 (84%) had stable disease as their best response by Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) cri-
teria (maintained for 6 months in most patients), for a
clinical benefit rate (complete response plus partial re-
sponse plus stable disease for6 months) of 73%. In seven
of the patients noted to have stable disease (16%), some de-
gree of objective tumor shrinkage was reported. In 39 pa-
tients who were symptomatic at baseline, subjective
improvement in symptoms was reported by 25 patients
(64%). In an intention-to-treat analysis, the median pro-
gression-free survival time was 32 weeks, with 38% of pa-
tients free from progression at 1 year, and 16% on treatment
at 18 months [71]. A series of 31 chordoma samples was
then analyzed, showing that PDGFR- was overexpressed
and activated in all cases, while PDGFR- and Kit were ex-
pressed less but activated [72]. Activating point mutations
were not found, confirming previous findings [73]. Casali
et al. [74] also reported that the addition of low-dose cispla-
tin to the treatment of patients with chordoma who pro-
gressed on imatinib restored sensitivity of the tumor,
suggesting synergism between imatinib and cisplatin.
Other signal transduction pathways that may provide
therapeutic targets include the epidermal growth factor re-
ceptor (EGFR) pathway, because strong expression of
EGFR and c-Met has been reported in 12 chordomas [75].
This was targeted in one patient treated with the combina-
tion of cetuximab and gefitinib with a good response [76].
Another anecdotal report involved the possibly antiangio-
genic therapy thalidomide in one patient achieving long-
term disease control [77].
CONCLUSION
Chordomas are rare primary bone tumors with a high risk
for local recurrence and modest propensity for distant me-
tastasis. Surgery is the primary modality to achieve the best
long-term control. However, the location of these tumors
makes en bloc excision to achieve adequate negative mar-
gins technically challenging. Conventional RT has a proven
role; however, the high doses required for these radioresis-
tant tumors lead to significant toxicity to surrounding nor-
mal tissues and limit its therapeutic value. Newer
techniques and charged particle radiotherapy allow for bet-
ter dose delivery, and hence better disease control. Cyto-
toxic chemotherapy has virtually no role in this disease;
however, molecularly targeted therapy is showing signifi-
cant promise and is an area of great potential.
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